274 related articles for article (PubMed ID: 32900355)
21. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
22. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
23. Mitochondria Participate in Chemoresistance to Cisplatin in Human Ovarian Cancer Cells.
Zampieri LX; Grasso D; Bouzin C; Brusa D; Rossignol R; Sonveaux P
Mol Cancer Res; 2020 Sep; 18(9):1379-1391. PubMed ID: 32471883
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.
Li S; Yang L; Wang J; Liang F; Chang B; Gu H; Wang H; Yang G; Chen Y
Oncotarget; 2016 Aug; 7(35):57145-57159. PubMed ID: 27494891
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
26. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
27. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum.
Sookram J; Zheng A; Linden KM; Morgan AB; Brown SA; Ostrovsky O
Int J Gynaecol Obstet; 2019 May; 145(2):225-232. PubMed ID: 30828803
[TBL] [Abstract][Full Text] [Related]
29. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM
J Ovarian Res; 2014; 7():45. PubMed ID: 24795781
[TBL] [Abstract][Full Text] [Related]
30. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
32. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.
Song M; Cui M; Liu K
Eur J Med Chem; 2022 Mar; 232():114205. PubMed ID: 35217497
[TBL] [Abstract][Full Text] [Related]
34. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
35. Extreme drug resistance is common after prior exposure to paclitaxel.
Geisler JP; Linnemeier GC; Thomas AJ; Manahan KJ
Gynecol Oncol; 2007 Sep; 106(3):538-40. PubMed ID: 17561236
[TBL] [Abstract][Full Text] [Related]
36. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
37. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
38. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
39. Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy.
Lam T; Aguirre-Ghiso JA; Geller MA; Aksan A; Azarin SM
Biotechnol Bioeng; 2020 Oct; 117(10):3066-3080. PubMed ID: 32589792
[TBL] [Abstract][Full Text] [Related]
40. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
